Prantae (Prantae Solutions) is a deep-tech diagnostics startup based in Bhubaneswar, India, that builds nanosensor-based testing devices for kidney health and other chronic conditions.

This Startup Deep Dive explains what Prantae does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Prantae in Brief

• What it is: Prantae is an Indian Deep-tech healthcare diagnostics company based in Bhubaneswar.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Prantae develops point-of-care healthcare diagnostics using proprietary nanosensor technology, IoT and AI.
• Its flagship Proflo-U is a kidney health assessment tool that detects levels from microalbumin to proteinuria; it is described as calibration-free, cost-effective and easy to use.
• Earlier products include EyeRa, an early detection platform for preeclampsia, and a 2019 profile also listed Salubrious (a solution for hidden hunger) and Embargo (detection of antibiotics in food products).
• Funding: Rs 5 crore seed (about USD 600K); grant funding also received.

Prantae Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Prantae?

Prantae operates in the Deep-tech healthcare diagnostics space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Prantae.

• Prantae develops point-of-care healthcare diagnostics using proprietary nanosensor technology, IoT and AI.
• Its flagship Proflo-U is a kidney health assessment tool that detects levels from microalbumin to proteinuria; it is described as calibration-free, cost-effective and easy to use.
• Earlier products include EyeRa, an early detection platform for preeclampsia, and a 2019 profile also listed Salubrious (a solution for hidden hunger) and Embargo (detection of antibiotics in food products).
• A 2019 profile described ProFolU as a smartphone-based self-monitoring device for kidney health.
• Reports also say a government technology development body signed a funding agreement for manufacturing and commercialisation of Proflo-U (amount not found).

The Origin Story of Prantae

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Sumona Karjee Mishra, Aseem Mishra.
• The company was founded in 2015 by Sumona Karjee Mishra and Aseem Mishra, based in Bhubaneswar.
• A 2019 profile says the idea grew out of the founder's own pregnancy complication (preeclampsia), after which she researched the condition and found no early diagnosis was available.
• It has received grants from DBT-BIRAC, DST, MeitY, Tata Trust, Millennium Alliance and Grand Challenge Exploration-India.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Deep-tech healthcare diagnostics sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2015: company founded in Bhubaneswar.
• 2019: profiled as a biotech startup working on affordable diagnoses for pregnant women, with EyeRa targeted for 2021 launch.
• FY2020-21: reported revenue of about Rs 1.29 crore.
• January 2025: raised Rs 5 crore (about USD 600K) seed round led by IAN Group, announced around 20 January 2025.
• One database dates the Rs 5 crore round to July 2023 while news reports date it to January 2025 (reports differ).

Prantae Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Seed, Rs 5 crore (about USD 600K), January 2025, led by IAN Group with IAN Alpha Fund, Samir Kalia, Deepank Kumar and Nitin Zamre (reported).
• Non-dilutive grants from DBT-BIRAC, DST, MeitY, Tata Trust, Millennium Alliance and Grand Challenge Exploration-India (amounts not found).
• One tracker lists USD 577K across one round (reports differ slightly on conversion).

How Does Prantae Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells point-of-care diagnostic devices and tests (Proflo-U) aimed at chronic disease management.
• Early funding has relied heavily on grants; the seed round is its first institutional equity round.
• Pricing, unit sales and channel details were not found in the sources read.

The Numbers: Prantae Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY2020-21 revenue about Rs 1.29 crore (reported by a trade publication).
• Seed round Rs 5 crore (about USD 600K), January 2025.

Market Opportunity for Prantae

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Targets chronic conditions such as chronic kidney disease, diabetes care and preeclampsia.
• India's point-of-care diagnostics market was cited at USD 1.41 billion in FY2024, projected to reach USD 2.71 billion by FY2032 (8.47% CAGR); the global market was cited at USD 30.87 billion in 2023 rising to USD 51.19 billion by 2032 (market-context figures from coverage, not Prantae-specific).

Technology and Product at Prantae

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Proprietary nanosensor technology combined with IoT and AI in the Proflo-U device.

Team and Culture at Prantae

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Founders Sumona Karjee Mishra and Aseem Mishra.
• An older profile cited 12 young engineers and two scientists.

Prantae Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Prantae vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Prantae

• The company is early stage with a small team and a first institutional round of Rs 5 crore.
• Revenue visibility is limited: the only revenue figure found is Rs 1.29 crore for FY2020-21.
• Coverage does not confirm commercial launch status or regulatory clearances for EyeRa or Proflo-U.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Prantae Growth Outlook: What to Watch

• Seed funds will support launch of complementary diagnostic solutions for kidney health and diabetes care, product portfolio expansion and R&D.
• The company plans to build a strong presence in India before going international.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Prantae can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Prantae Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Prantae

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Prantae.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Prantae

Studying a company in the Deep-tech healthcare diagnostics space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Prantae.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Prantae as a Startup

• Customer clarity: Can Prantae name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Prantae is part of India’s growing Deep-tech healthcare diagnostics ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Prantae FAQs: Frequently Asked Questions

What is Prantae?

Prantae (Prantae Solutions) is a deep-tech diagnostics startup based in Bhubaneswar, India, that builds nanosensor-based testing devices for kidney health and other chronic conditions. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Prantae?

Prantae was founded by Sumona Karjee Mishra, Aseem Mishra, and the company reports a founding year of 2015.

How much funding has Prantae raised?

Rs 5 crore seed (about USD 600K); grant funding also received. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Prantae make money?

Prantae earns revenue from its Deep-tech healthcare diagnostics products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Prantae?

Competitors of Prantae depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Prantae?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: EtherealX — Bengaluru startup building a fully reusable rocket | Credila — Credila nearly doubled profit to Rs 990 crore in FY25 and holds about 62% of NBFC education loans. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.